Drug Profile
Research programme: pulmonary arterial hypertension therapies - Sagene
Latest Information Update: 30 Dec 2022
Price :
$50
*
At a glance
- Originator Sagene Pharmaceuticals
- Class Antihypertensives; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pulmonary arterial hypertension
Most Recent Events
- 30 Dec 2022 Discontinued - Preclinical for Pulmonary arterial hypertension in USA (unspecified route) (Sagene Pharmaceuticals pipeline; December 2022)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA
- 28 Feb 2018 Preclinical development is still ongoing in pulmonary-arterial-hypertension in USA (Sagene Pharmaceuticals pipeline, February 2018)